Cargando…

Should Academic Emergency Departments Collaborate in Pharmaceutical Industry-Sponsored Research?: The Dangers of Industry-Funded Research in Emergency Medicine

Detalles Bibliográficos
Autores principales:	Stone, Susan, Herbert, Mel
Formato:	Texto
Lenguaje:	English
Publicado:	California Chapter of the American Academy of Emergency Medicine 2003
Materias:	Pro/Con
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906962/ https://www.ncbi.nlm.nih.gov/pubmed/20847847

Ejemplares similares

Interacting with the Pharmaceutical Industry
por: Hayden, Stephen R.
Publicado: (2003)

Pro: Venoarterial ECMO Should Be Considered in Patients With COVID-19
por: Bhatia, Meena, et al.
Publicado: (2021)

Con: Venoarterial ECMO Should Not Be Considered in Patients With COVID-19
por: McLean, Duncan J., et al.
Publicado: (2021)

Con: Should Evidence-Based Medicine Be Used More in Clinical Practice?
por: Maxim, Preston
Publicado: (2006)

Pro: Should Evidence-Based Medicine Be Used More in Clinical Practice?
por: Fee, Chris
Publicado: (2006)

Con: Integrated 5-Year Anesthesiology Residency Should Be Implemented Widely
por: Phillips, Thomas
Publicado: (2023)

Pro: Integrated Five-Year Anesthesiology Residency Should Be Implemented Widely
por: Kovar, Alan J., et al.
Publicado: (2023)

Why the US Government Should Not Adopt a Universal Health Coverage Program
por: Montauk, Lance
Publicado: (2004)

Should we offer preventive treatment to all carriers of PLN p.(Arg14del) variant?: Pro: Provide pre-emptive treatment to asymptomatic carriers
por: de Boer, Rudolf A.
Publicado: (2023)

Advantages of a Three-year Residency
por: Langdorf, Mark, et al.
Publicado: (2004)

Rebuttal of Con
por: Fee, Chris
Publicado: (2006)

Rebuttal of Pro
por: Maxim, Preston
Publicado: (2006)

Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere!
por: Rossignol, Patrick, et al.
Publicado: (2023)

Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy
por: Zand, Ladan, et al.
Publicado: (2023)

Should we offer preventive treatment to all carriers of PLN p.(Arg14del) variant?: Con: Do no harm to asymptomatic carriers
por: Doevendans, Pieter A.
Publicado: (2023)

The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research
por: Flick, E Dawn, et al.
Publicado: (2023)

Saying No to Cameras in the Emergency Department
por: Geiderman, Joel
Publicado: (2003)

Industry-Sponsored Research: Author's Reply
por: Sotelo, Julio
Publicado: (2006)

Why the US Should Adopt a Universal Health Care Coverage Program
por: Brown, Lance
Publicado: (2004)

Dietary sodium and cardiovascular and renal disease risk factors: dark horse or phantom entry?
por: McCarron, David A.
Publicado: (2008)

Is too much salt harmful? Yes
por: Agócs, Róbert, et al.
Publicado: (2019)

Pro con debates in clinical medicine infection prevention and control in cystic fibrosis: One size fits all? The argument in favour
por: Haggie, S., et al.
Publicado: (2020)

Congenital nephrotic syndrome: is early aggressive treatment needed? Yes
por: Hölttä, Tuula, et al.
Publicado: (2020)

Anthracyclines in the treatment of patients with early breast cancer
por: Guarneri, V., et al.
Publicado: (2022)

The term CAKUT has outlived its usefulness: the case for the prosecution
por: Woolf, Adrian S.
Publicado: (2022)

The term CAKUT has outlived its usefulness: the case for the defense
por: Knoers, Nine V. A. M.
Publicado: (2022)

FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer
por: Cervantes, A., et al.
Publicado: (2023)

Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy
por: Oing, C., et al.
Publicado: (2023)

Therapy of membranous nephropathy: quo vadis?
por: Glassock, Richard J
Publicado: (2023)

The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab
por: Alberici, Federico, et al.
Publicado: (2023)

When comparing the safety of drugs, don't forget the exposure dimension
por: Zoccali, Carmine
Publicado: (2023)

Pharmacological strategies to manage hyperkalaemia: out with the old, in with the new? Not so fast…
por: Carrero, Juan Jesus, et al.
Publicado: (2023)

Industry-Sponsored Research: A More Comprehensive Alternative
por: Mansfield, Peter
Publicado: (2006)

Academic Scientists and the Pharmaceutical Industry: Cooperative Research in Twentieth-Century America
por: Ford, James M.
Publicado: (1988)

Academic scientists and the pharmaceutical industry: cooperative research in twentieth-century America
por: Weatherall, M.
Publicado: (1989)

Of Sophists and Spin-Doctors: Industry-Sponsored Ghostwriting and the Crisis of Academic Medicine
por: McHenry, Leemon
Publicado: (2010)

Pitfalls and Safeguards in Industry-Funded Research
por: Breault, Joseph L., et al.
Publicado: (2020)

Industry - from sponsor to provider?
por: Griebenow, Reinhard
Publicado: (2017)

The Influence of Emerging Markets on the Pharmaceutical Industry
por: Tannoury, Maya, et al.
Publicado: (2017)

Fomepizole should not be used more liberally in paracetamol overdose
por: Dear, James W.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qafhpnh6a5k6pvqvu4fjsip1l5